Skip to search formSkip to main contentSkip to account menu

MDL 899

Known as: MDL-899 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

mopidralazine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions.
1986
1986
Hemodynamic profile of N-(2,5-dimethyl-1H-pyrrol-1-yl)6-(4-morpholinyl)-3-pyridazinamine hydrochloride in conscious dogs.
The effects of N-(2,5-dimethyl-1H-pyrrol-1-yl)6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899) on systemic, pulmonary… 
1985
1985
Pharmacological studies of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator.
N-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899) is a new long-acting antihypertensive… 
1985
1985
Clinical Evaluation of the Vasodilator MDL-899 in Patients with Essential Hypertension
Summary: In this study of 10 patients with essential hypertension inadequately controlled by standard β-blocker–diuretic… 
1985
1985
Pharmacokinetics of a new antihypertensive pyrrolyl pyridazinamine (MDL-899) in the rat and the dog.
The pharmacokinetics of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new… 
1983
1983
Pharmacodynamic Studies in Normal Volunteers with MDL‐899, a New Arteriolar Vasodilator
Summary We conducted pharmacodynamic studies with a new vasodilator, MDL-899. Following initial dose-ranging studies we studied… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)